Phase-2 prospective trial using SABR (upto 20 Gy × 3 Fc) for inoperable HCC as a local salvage after incomplete transarterial chemoembolization in 50 patients.
Complete response and partial response rates were 38.3% and 38.3% each. At 2 years, the LC, OS, and PFS were 94.6%, 68.7%, and 33.8%, respectively. The toxicity rates were 6.4% and 4.3% for grade-3 and 4 toxicity. Demonstrated feasibility of SBRT after incomplete TACE for inoperable HCC.
10 patients were given SABR (mean dose 51 Gy in 3 Fc) during wait for definitive transplantation.
Post-SABR excision revealed a complete response rate of 27%. There was no progression in any case which had not attained complete response. SABR prevents progression in patients of HCC awaiting definitive transplantation.
60 patients with HCC treated with SABR (doses of 14 Gy × 3 Fc for patients with Child-Turcotte-Pugh Class A; 8 Gy × 5 Fc for Class B).
2-year LC, PFS, and OS were 90%, 48%, and 67%, respectively. 23 patients underwent transplantation subsequently. Concluded that SABR is a safe, effective, and noninvasive option for patients with HCC <6 cm.
Assessed use of SABR as a bridge to transplantation in 10 HCC patients using personalized dose-fractionation to spare uninvolved liver, while preventing progression of HCC.
No treated lesion progressed after treatment and, hence, SABR can be considered as an effective bridge to hepatic transplantation, for patients on waiting lists for subsequent hepatic transplantation.
